Odds ratios of anti-TNF-α therapy survival at 4 years. Results of various univariate and multivariate logistic regression analyses. Final multivariate models were found by stepwise regression.
| Univariate | Multivariate | |||
|---|---|---|---|---|
| Baseline Variables | OR (95% CI) | p | OR (95% CI) | p |
| Sex: female vs male | 1.15 (0.79–1.65) | 0.46 | 1.3 (0.85–1.97) | 0.22 |
| Disease duration, yrs | 0.99 (0.69–1.00) | 0.054 | 0.98 (0.96–0.99) | 0.02 |
| ESR | 1.00 (0.99–1.00) | 0.69 | 1.01 (0.99–1.02) | 0.14 |
| DAS28 | 0.99 (0.90–1.09) | 0.85 | 0.95 (0.85–1.06) | 0.37 |
| Comorbidities: yes vs no | 0.67 (0.50–0. 87) | 0.003 | 0.77 (0.56–1.05) | 0.10 |
| Glucocorticoids: yes vs no | 0.76 (0.57–1.00) | 0.05 | 1.18 (0.83–1.67) | 0.39 |
| DMARD: yes vs no | 0.51 (0.38–0.68) | 0.0001 | 0.64 (0.43–0.93) | 0.02 |
| MTX: yes vs no | 0.61 (0.46–0.81) | 0.0007 | 0.58 (0.41–0.82) | 0.02 |
TNF: tumor necrosis factor; ESR: erythrocyte sedimentation rate; DAS28: Disease Activity Score based on 28 joints; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate.